WeissCom Adds New Healthcare Business
Charting the future of public relations
Holmes Report
CEO

WeissCom Adds New Healthcare Business

WeissComm Partners, the fast-growing healthcare communications agency, has added several new accounts, including Actelion Pharmaceuticals US, Cell Therapeutics, Onyx Pharmaceuticals and Medivation.

Paul Holmes

SAN FRANCISCO—WeissComm Partners, the fast-growing healthcare communications agency, has added several new accounts, including Actelion Pharmaceuticals US, Cell Therapeutics, Onyx Pharmaceuticals and Medivation. WeissComm is providing a wide range of services for its new clients, including disease and clinical trial awareness; data communications planning and media relations; national and grass roots product communications support; and corporate, investor and advocacy relations.

“We selected WeissComm because of its strong track record and experience in biopharmaceutical and healthcare communications,” says C. Patrick Machado, senior vice president and chief financial officer of Medivation, a publicly-traded company developing a portfolio of small molecule drugs for major unmet medical needs, including Alzheimer’s disease. “Its unique ability to support all aspects of our evolving business priorities—from raising corporate visibility to driving clinical, business and product marketing communications—clearly differentiated the firm.”

View Style:

Load 3 More
comments powered by Disqus